The KRAS G12C mutation is of particular interest as it could represent a subgroup of a similar size to EGFR mutations (10–15%), and the KRAS G12C inhibitor, AMG 510, has shown promising activity in a phase I trial in NSCLC [20]. Here, EGFR is linked to non-small cell lung carcinoma.